Anteris Technologies Global Corp (AVR)

$9.04 +0.32 (3.67%)
Market Cap 881.02M
Revenue (ttm) 1.91M
Net Income (ttm) -94.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,928.80%
Debt to Equity Ratio 0.00
Volume 362,900
Avg Vol 1,040,968
Day's Range N/A - N/A
Shares Out 97.46M
Stochastic %K 66%
Beta 1.80
Analysts Strong Sell
Price Target $15.80

Company Profile

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into dura...

Industry: Medical Devices
Sector: Healthcare
Phone: 61 7 3152 3200
Address:
Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong, Australia
Orlandotrader
Orlandotrader Aug. 31 at 7:21 PM
$AVR Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Cantor Global Healthcare Conference Wednesday, September 9, 2026 (US time) Format: Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings Time: 11:30AM (US EST) Wells Fargo Healthcare Conference Thursday, September 10, 2026 (US time) Format: Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings Time: 9:30AM (US EST)
0 · Reply
Templar57
Templar57 Aug. 20 at 12:31 PM
$AVR my AI generated price targets Successful AVR scenario Potential range. 2026–27 PARADIGM de-risking $15–40 2028 Strong pivotal/durability evidence $35–70 2029 Regulatory visibility $60–110 2030 Approval/commercial launch $90–150 2031–33 Medtronic-enabled adoption $140–225 2032–35 Category leadership\platform expansion $200–300+ Acquisition Strategic premium potentially $250–350+
0 · Reply
Templar57
Templar57 Aug. 20 at 2:20 AM
$AVR DurAVR may have an architectural advantage that is substantially more difficult to replicate than an incremental engineering feature. If the important variable becomes true biomimetic leaflet geometry and physiologic flow, incumbents may need significant redesigns and new pivotal programs rather than simple product iterations. That could provide Anteris with a multi-year technological window.
0 · Reply
Templar57
Templar57 Aug. 14 at 8:10 PM
$AVR Firm Rating Target Barclays - Overweight $18 Wells Fargo Overweight $16 Cantor Fitzgerald — Overweight $15 TD Cowen Buy $15
1 · Reply
Templar57
Templar57 Aug. 12 at 12:53 PM
$AVR lack of information on their site activation and patient enrollment from the Q2 update is a little concerning. Hoping there is a formal announcment on Friday from Wayne to add more details. Would have been nice to hear how Paradigm is progressing and if they feel that that everything is on schedule.
0 · Reply
Orlandotrader
Orlandotrader Aug. 12 at 1:16 AM
$AVR Looks to be trading .40 cents higher in Australia. 12.94.
0 · Reply
Orlandotrader
Orlandotrader Aug. 12 at 12:52 AM
$AVR Looks like a Slow start to this Trial. 40 Million cash burn? Anteris recorded net operating cash outflows of US$20.8 million for the 3 months to June 30, primarily related to clinical, regulatory and manufacturing requirements for PARADIGM. Research and development expenses totalled US$23.4 million, reflecting increased manufacturing and quality capabilities, process development and validation work, additional headcount and costs associated with patient enrolment and expansion of its field-based clinical team. No Bueno!!!! Afraid we are taking a hit in the morning. Did not post Recruitment numbers???? Not Good cash management? Where am I wrong.
2 · Reply
focafoca99
focafoca99 Aug. 11 at 11:33 PM
$AVR posted Q2 2026 results, highlighting Medicare coverage win for its PARADIGM trial.
2 · Reply
Orlandotrader
Orlandotrader Aug. 7 at 9:30 PM
$AVR Text book correction from an OverBought Weekly chart From 70 back to 50 on RSI. Held MidLine Bollinger Band. If possible Add on dips back to 8.25.
1 · Reply
ChartingRockets
ChartingRockets Aug. 6 at 7:07 PM
$AVR 10$+ pls
1 · Reply
Latest News on AVR
Anteris to Present at September Healthcare Investor Conferences

Aug 31, 2026, 2:45 PM EDT - 5 days ago

Anteris to Present at September Healthcare Investor Conferences

Anteris Technologies Announces Results for the Second Quarter of 2026

Aug 11, 2026, 7:00 PM EDT - 25 days ago

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies files to sell 5.39M shares of common stock

2026-07-01T21:15:10.000Z - 2 months ago

Anteris Technologies files to sell 5.39M shares of common stock

Anteris Technologies cleared by ANSM for DurAVR THV trial

2026-06-08T10:12:00.000Z - 3 months ago

Anteris Technologies cleared by ANSM for DurAVR THV trial

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Jun 8, 2026, 6:00 AM EDT - 3 months ago

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Anteris Technologies price target raised to $18 from $17 at Barclays

2026-05-15T08:55:46.000Z - 3 months ago

Anteris Technologies price target raised to $18 from $17 at Barclays

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

May 13, 2026, 8:39 AM EDT - 3 months ago

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

Anteris Announces Results for the First Quarter of 2026

May 12, 2026, 7:00 PM EDT - 3 months ago

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies: First U.S. patients treated in global PARADIGM trial

2026-05-05T10:28:40.000Z - 4 months ago

Anteris Technologies: First U.S. patients treated in global PARADIGM trial

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

May 5, 2026, 6:00 AM EDT - 4 months ago

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies secures CMS reimbursement for trial site activation

2026-04-28T10:33:20.000Z - 4 months ago

Anteris Technologies secures CMS reimbursement for trial site activation

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Apr 28, 2026, 6:00 AM EDT - 4 months ago

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies assumed with an Overweight at Cantor Fitzgerald

2026-03-12T11:35:42.000Z - 5 months ago

Anteris Technologies assumed with an Overweight at Cantor Fitzgerald

Anteris Technologies initiated with an Overweight at Wells Fargo

2026-03-11T11:01:12.000Z - 5 months ago

Anteris Technologies initiated with an Overweight at Wells Fargo

Anteris Reports 2025 Financial Results and Provides Corporate Update

Feb 26, 2026, 6:00 PM EST - 6 months ago

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Technologies price target lowered to $17 from $22 at Barclays

2026-02-23T14:26:31.000Z - 6 months ago

Anteris Technologies price target lowered to $17 from $22 at Barclays

Anteris Technologies price target lowered to $15 from $20 at Lake Street

2026-01-23T14:01:04.000Z - 7 months ago

Anteris Technologies price target lowered to $15 from $20 at Lake Street

MDT

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Jan 22, 2026, 4:02 PM EST - 7 months ago

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Jan 22, 2026, 4:01 PM EST - 7 months ago

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

Jan 20, 2026, 10:53 PM EST - 7 months ago

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

Anteris Technologies announces $200M common stock offering

2026-01-20T21:11:59.000Z - 7 months ago

Anteris Technologies announces $200M common stock offering

Anteris Technologies files $500M mixed securities shelf

2026-01-02T22:25:14.000Z - 8 months ago

Anteris Technologies files $500M mixed securities shelf

Anteris Technologies files to sell 9.1M shares of common stock for holders

2025-11-26T21:40:22.000Z - 9 months ago

Anteris Technologies files to sell 9.1M shares of common stock for holders

Anteris Technologies Presents Data from 100 DurAVR(R) THV Patients at PCR London

2025-11-17T11:10:50.000Z - 9 months ago

Anteris Technologies Presents Data from 100 DurAVR(R) THV Patients at PCR London

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

Nov 17, 2025, 6:00 AM EST - 9 months ago

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

Anteris Announces Results for the Third Quarter of 2025

Nov 12, 2025, 5:52 PM EST - 9 months ago

Anteris Announces Results for the Third Quarter of 2025

Anteris Technologies reports clinical outcomes for DurAVR THV in patients

2025-10-28T22:20:19.000Z - 10 months ago

Anteris Technologies reports clinical outcomes for DurAVR THV in patients

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Oct 27, 2025, 5:43 PM EDT - 10 months ago

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Oct 27, 2025, 8:43 AM EDT - 10 months ago

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Sep 19, 2025, 2:30 AM EDT - 11 months ago

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Sep 11, 2025, 8:50 AM EDT - 12 months ago

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Anteris Announces Results for the Second Quarter of 2025

Aug 11, 2025, 4:52 PM EDT - 1 year ago

Anteris Announces Results for the Second Quarter of 2025

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Jun 9, 2025, 10:52 PM EDT - 1 year ago

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Mar 31, 2025, 7:15 AM EDT - 1 year ago

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

Anteris Reports 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 8:33 PM EDT - 1 year ago

Anteris Reports 2024 Financial Results and Provides Corporate Update

Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

Dec 16, 2024, 7:49 PM EST - 1 year ago

Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering

Dec 12, 2024, 10:34 PM EST - 1 year ago

Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering

Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering

Dec 9, 2024, 7:43 AM EST - 1 year ago

Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering

Orlandotrader
Orlandotrader Aug. 31 at 7:21 PM
$AVR Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Cantor Global Healthcare Conference Wednesday, September 9, 2026 (US time) Format: Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings Time: 11:30AM (US EST) Wells Fargo Healthcare Conference Thursday, September 10, 2026 (US time) Format: Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings Time: 9:30AM (US EST)
0 · Reply
Templar57
Templar57 Aug. 20 at 12:31 PM
$AVR my AI generated price targets Successful AVR scenario Potential range. 2026–27 PARADIGM de-risking $15–40 2028 Strong pivotal/durability evidence $35–70 2029 Regulatory visibility $60–110 2030 Approval/commercial launch $90–150 2031–33 Medtronic-enabled adoption $140–225 2032–35 Category leadership\platform expansion $200–300+ Acquisition Strategic premium potentially $250–350+
0 · Reply
Templar57
Templar57 Aug. 20 at 2:20 AM
$AVR DurAVR may have an architectural advantage that is substantially more difficult to replicate than an incremental engineering feature. If the important variable becomes true biomimetic leaflet geometry and physiologic flow, incumbents may need significant redesigns and new pivotal programs rather than simple product iterations. That could provide Anteris with a multi-year technological window.
0 · Reply
Templar57
Templar57 Aug. 14 at 8:10 PM
$AVR Firm Rating Target Barclays - Overweight $18 Wells Fargo Overweight $16 Cantor Fitzgerald — Overweight $15 TD Cowen Buy $15
1 · Reply
Templar57
Templar57 Aug. 12 at 12:53 PM
$AVR lack of information on their site activation and patient enrollment from the Q2 update is a little concerning. Hoping there is a formal announcment on Friday from Wayne to add more details. Would have been nice to hear how Paradigm is progressing and if they feel that that everything is on schedule.
0 · Reply
Orlandotrader
Orlandotrader Aug. 12 at 1:16 AM
$AVR Looks to be trading .40 cents higher in Australia. 12.94.
0 · Reply
Orlandotrader
Orlandotrader Aug. 12 at 12:52 AM
$AVR Looks like a Slow start to this Trial. 40 Million cash burn? Anteris recorded net operating cash outflows of US$20.8 million for the 3 months to June 30, primarily related to clinical, regulatory and manufacturing requirements for PARADIGM. Research and development expenses totalled US$23.4 million, reflecting increased manufacturing and quality capabilities, process development and validation work, additional headcount and costs associated with patient enrolment and expansion of its field-based clinical team. No Bueno!!!! Afraid we are taking a hit in the morning. Did not post Recruitment numbers???? Not Good cash management? Where am I wrong.
2 · Reply
focafoca99
focafoca99 Aug. 11 at 11:33 PM
$AVR posted Q2 2026 results, highlighting Medicare coverage win for its PARADIGM trial.
2 · Reply
Orlandotrader
Orlandotrader Aug. 7 at 9:30 PM
$AVR Text book correction from an OverBought Weekly chart From 70 back to 50 on RSI. Held MidLine Bollinger Band. If possible Add on dips back to 8.25.
1 · Reply
ChartingRockets
ChartingRockets Aug. 6 at 7:07 PM
$AVR 10$+ pls
1 · Reply
Templar57
Templar57 Aug. 6 at 4:59 PM
$AVR FMR LLC—the parent company of Fidelity Investments—reported beneficial ownership of approximately 7.33 million Anteris shares, representing 7.5% of the company, as of June 30. The filing states the shares are held in the ordinary course of business and not to influence control of Anteris. That is likely contributing to today’s 5% rise, because it confirms that a major global investment institution has accumulated a meaningful position. It is a positive validation signal, although the position may be spread across several Fidelity-managed funds rather than representing one concentrated strategic investment.
0 · Reply
Templar57
Templar57 Aug. 4 at 3:01 AM
$AVR Q2 Aug 14th
0 · Reply
Orlandotrader
Orlandotrader Aug. 3 at 6:14 PM
$AVR Daddy Like!
0 · Reply
focafoca99
focafoca99 Aug. 3 at 1:12 PM
$AVR mentioned court orders granted in an ASX filing.
0 · Reply
Templar57
Templar57 Aug. 1 at 7:48 PM
$AVR Value, potential advancements, longevity, Paradigm - Valve in Valve, Hemodynamics, EOA, potential for younger patient populations, expansion benefits for HF patients. Type these into an AI engine, ask for conservative, base and bull. 2026-2040.
2 · Reply
Templar57
Templar57 Jul. 31 at 6:19 PM
$AVR I know the past data doesn’t mean that execution will be smooth. If the previous data is supportive and validating, along with future TAM expansion and TAVR CAGR, the value could be exlosive. I am long and accumulating!! Waiting for positive validation
3 · Reply
Orlandotrader
Orlandotrader Jul. 28 at 2:52 PM
$AVR 500 More at 7.78. Load baby!!!!!
0 · Reply
DebbyEsther
DebbyEsther Jul. 28 at 1:43 PM
$AVR $28.75M Massive Insider Buy: Smart Money Loading Up Fast! Insider L1 Capital just dropped $28.75M to snap up 5,000,000 shares of$AVR! Shares coiling intraday through the $7.89-$8.34 demand range. Heavy institutional & insider accumulation happening right at key support as smart money prepares for the next breakout leg! Major moves often begin quietly. Stay connected and don't miss key moments.
2 · Reply
Orlandotrader
Orlandotrader Jul. 27 at 9:24 PM
$AVR Execution Update coming in August. Let’s see if we are up to Date with Year EndTrial Recruitment of 1,000 Trial participants. Hope cash burn is around 3 Million per Quarter.
1 · Reply
Orlandotrader
Orlandotrader Jul. 21 at 6:53 PM
$AVR Added 1,000 at 8.17. Watching closely to add another 1,000 . Bottom could be in.
1 · Reply
Orlandotrader
Orlandotrader Jul. 19 at 7:55 PM
$AVR Might be Greedy but looking to Load more between 7.25-7.75. A weak XBI might get us there. Long Term Extremely Positive as this New Valve will Most Likely set the Standard for the TAVR procedure.
0 · Reply
Orlandotrader
Orlandotrader Jul. 14 at 1:56 PM
$AVR The Roll!!! Looking to test the 50 Day at 8.80. Will be Loading at lower 8$ range.
0 · Reply